DS3610a for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is designed to assess the safety, tolerability, and efficacy of DS3610a, given as a single agent to participants with advanced or metastatic solid tumors.
Are You a Good Fit for This Trial?
This trial is for adults with advanced or metastatic solid tumors who have not responded to, cannot tolerate, or have relapsed after standard treatments. Participants must be able to provide a tumor tissue sample and have measurable disease on recent scans.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- DS3610a
Trial Overview
The study is testing DS3610a as a single drug treatment in people with advanced solid tumors. The main goals are to see how safe it is, what side effects it causes, and if it helps control the cancer.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will receive DS3610a at escalating doses. The RDE will be determined using data collected from this arm.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Daiichi Sankyo
Lead Sponsor
Hiroyuki Okuzawa
Daiichi Sankyo
Chief Executive Officer
Degree in Social Sciences from Hitotsubashi University
Yuki Abe
Daiichi Sankyo
Chief Medical Officer since 2023
MD
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.